Increasing Demand for Organ Transplantation and Funding for R&D of Next-Generation Sequencing Assays to Augment Growth of Transplant Diagnostics Market
One of the primary reasons for the growth and success of the field of transplant diagnostics is due to the developments and improvements in the various technologies used by these assays. The advent of molecular assays and DNA probes has resulted in the development of more sensitive and powerful techniques for analyzing and evaluating tissue samples from patients. In particular, the use of polymerase chain reactions and enzyme-linked immunosorbent assays (ELISA, EIA) has provided doctors with more information about the organ systems in which they are evaluating tissues. Molecular assays have also enabled scientists to examine living organs under the microscope and to test for pathogenicity and virulence factors of different pathogens.
Market Dynamics
Increasing
demand for organ transplantation is expected to propel growth of the transplant diagnostics market. For instance, according to the U.S. Government Information
on Organ Donation and Transplantation, over 112,000 patients are on the
national transplant waiting list as of March 2020.
Increasing
funding for R&D of next-generation sequencing assay for monitoring graft
status is expected to offer lucrative growth opportunities for players in the transplant
diagnostics market. For instance, in January 2021, Devyser Diagnostics received a US$ 909,000 grant
through the Eurostars-2 program to develop a next-generation sequencing assay
for monitoring graft status and early detection of rejection in kidney
transplant recipients.
High
cost of organ transplant is expected to hinder growth of the transplant
diagnostics market. For instance, according to American Heart Association 2019
Heart Disease and Stroke Statistics, mean hospital charge for heart transplant
in the U.S. was US$ 808,770.
Among
regions, North America is expected to witness significant growth in the transplant
diagnostics market, owing to increasing number of organ transplant. For instance,
according to the Organ Procurement and Transplantation Network (OPTN)/ The
Scientific Registry of Transplant Recipients (SRTR), in 2015, 2016, and 2019,
the U.S. recorded over 30,000 transplants per year.
Competitive Analysis
Major
players operating in the transplant diagnostics market include, Thermo Fisher
Scientific, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., F. Hoffman-La Roche
Ltd., Immucor, Inc., Becton Dickinson and Company, bioMérieux S.A., Illumina,
Inc., Verici Dx, CareDx, Inc., and GenDx.
Major
players operating in the transplant diagnostics market are focused on adopting
various strategies to enhance their market share. For instance, in January
2021, Verici Dx expanded the scope of its license agreement with the Icahn
School of Medicine at Mount Sinai Health System, a New York City-based academic
medical system, to include an additional patent filing.
Comments
Post a Comment